Author

Josef Scheiber

Managing Director at BioVariance GmbH - Cited by 1,925 - Pharmacogenomics - Drug Interactions - Bioinformatics - Cheminformatics

Biography

Dr. Josef Scheiber is the Founder and Managing Director of BioVariance, which he grew from a one-man company to a 26-people organization within a bit less than three years. He holds a PhD in Pharmaceutical Data Analytics from the Department of Pharmacy at the University of Würzburg in Germany and a MSc in Bioinformatics from the University of Regensburg.
Title
Cited by
Year
Analysis of pharmacology data and the prediction of adverse drug reactions and off‐target effects from chemical structure
A Bender, J Scheiber, M Glick, JW Davies, K Azzaoui, J Hamon, L Urban, ...ChemMedChem: Chemistry Enabling Drug Discovery 2 (6), 861-873, 2007200
367
2007
How similar are similarity searching methods? A principal component analysis of molecular descriptor space
A Bender, JL Jenkins, J Scheiber, SCK Sukuru, M Glick, JW DaviesJournal of chemical information and modeling 49 (1), 108-119, 2009200
312
2009
Targeting acetylcholinesterase to treat neurodegeneration
U Holzgrabe, P Kapková, V Alptüzün, J Scheiber, E KugelmannExpert opinion on therapeutic targets 11 (2), 161-179, 2007200
215
2007
Mapping adverse drug reactions in chemical space
J Scheiber, JL Jenkins, SCK Sukuru, A Bender, D Mikhailov, M Milik, ...Journal of medicinal chemistry 52 (9), 3103-3107, 2009200
192
2009
Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis
J Scheiber, B Chen, M Milik, SCK Sukuru, A Bender, D Mikhailov, ...Journal of chemical information and modeling 49 (2), 308-317, 2009200
183
2009
Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity
SCK Sukuru, JL Jenkins, REJ Beckwith, J Scheiber, A Bender, ...Journal of biomolecular screening 14 (6), 690-699, 2009200
87
2009
Which aspects of HTS are empirically correlated with downstream success?
A Bender, D Bojanic, JW Davies, TJ Crisman, D Mikhailov, J Scheiber, ...Current Opinion in Drug Discovery and Development 11 (3), 327, 2008200
74
2008
Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data
TJ Crisman, CN Parker, JL Jenkins, J Scheiber, M Thoma, ZB Kang, ...Journal of chemical information and modeling 47 (4), 1319-1327, 2007200
74
2007
Aziridide‐Based Inhibitors of Cathepsin L: Synthesis, Inhibition Activity, and Docking Studies
R Vicik, M Busemann, C Gelhaus, N Stiefl, J Scheiber, W Schmitz, ...ChemMedChem: Chemistry Enabling Drug Discovery 1 (10), 1126-1141, 2006200
68
2006
Interaction of (benzylidene-hydrazono)-1, 4-dihydropyridines with β-amyloid, acetylcholine, and butyrylcholine esterases
V Alptüzün, M Prinz, V Hörr, J Scheiber, K Radacki, A Fallarero, P Vuorela, ...Bioorganic & medicinal chemistry 18 (5), 2049-2059, 2010201
65
2010
Charge interactions do the job: a combined statistical and combinatorial approach to finding artificial receptors for binding tetrapeptides in water
C Schmuck, M Heil, J Scheiber, K BaumannAngewandte Chemie International Edition 44 (44), 7208-7212, 2005200
45
2005
“Virtual fragment linking”: an approach to identify potent binders from low affinity fragment hits
TJ Crisman, A Bender, M Milik, JL Jenkins, J Scheiber, SCK Sukuru, ...Journal of medicinal chemistry 51 (8), 2481-2491, 2008200
43
2008
NMR spectroscopic and molecular modelling studies on cyclodextrin–dipeptide inclusion complexes
C Kahle, R Deubner, C Schollmayer, J Scheiber, K Baumann, ...European journal of organic chemistry 2005 (8), 1578-1589, 2005200
35
2005
Cis‐Configured Aziridines Are New Pseudo‐Irreversible Dual‐Mode Inhibitors of Candida albicans Secreted Aspartic Protease 2
B Degel, P Staib, S Rohrer, J Scheiber, E Martina, C Büchold, K Baumann, ...ChemMedChem: Chemistry Enabling Drug Discovery 3 (2), 302-315, 2008200
35
2008
Comparison of cyclodextrin‐dipeptide inclusion complexes in the absence and presence of urea by means of capillary electrophoresis, nuclear magnetic resonance and molecular …
B Waibel, J Scheiber, C Meier, M Hammitzsch, K Baumann, GKE Scriba, ...European journal of organic chemistry 2007 (18), 2921-2930, 2007200
28
2007
Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data
A Bender, D Mikhailov, M Glick, J Scheiber, JW Davies, S Cleaver, ...Journal of proteome research 8 (5), 75-85, 2009200
25
2009
SARS‐CoV‐2 infections in cancer outpatients—Most infected patients are asymptomatic carriers without impact on chemotherapy
L Hempel, A Piehler, MW Pfaffl, J Molnar, B Kirchner, S Robert, J Veloso, ...Cancer Medicine 9 (21), 8020-8028, 2020202
15
2020
Ladungswechselwirkungen machen es möglich: ein kombinierter statistischer und kombinatorischer Ansatz zur Auffindung künstlicher Rezeptoren für die Bindung von Tetrapeptiden in …
C Schmuck, M Heil, J Scheiber, K BaumannAngewandte Chemie 117 (44), 7374-7379, 2005200
14
2005
xMaP An Interpretable Alignment-Free Four-Dimensional Quantitative Structure–Activity Relationship Technique Based on Molecular Surface Properties and Conformer Ensembles
J Dreher, J Scheiber, N Stiefl, K BaumannJournal of Chemical Information and Modeling 58 (1), 165-181, 2018201
10
2018
Chemogenomic analysis of safety profiling data
J Scheiber, JL JenkinsChemogenomics: Methods and Applications, 207-223, 20020
9
2009

Referred From: https://scholar.google.com/citations?user=gI2lur0AAAAJ&hl=en

Cited by
Citations 1925
h-index 16
i10-index 19
Recommended Journals
Open Access Journals